Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid

Authors: Arnaud Scherpereel, Bogdan Dragos Grigoriu, Marc Noppen, Thomas Gey, Bachar Chahine, Simon Baldacci, Jacques Trauet, Marie-Christine Copin, Jean-Paul Dessaint, Henri Porte, Myriam Labalette

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Malignant pleural effusions (MPE) are a common and fatal complication in cancers including lung or breast cancers, or malignant pleural mesothelioma (MPM). MPE animal models and immunotherapy trials in MPM patients previously suggested defects of the cellular immunity in MPE. However only few observational studies of the immune response were done in MPM patients, using questionable control groups (transudate…).

Methods

We compared T cell populations evaluated by flow cytometry from blood and pleural effusion of untreated patients with MPM (n = 58), pleural metastasis of adenocarcinoma (n = 30) or with benign pleural lesions associated with asbestos exposure (n = 23). Blood and pleural fluid were also obtained from healthy subjects, providing normal values for T cell populations.

Results

Blood CD4+ or CD8+ T cells percentages were similar in all groups of patients or healthy subjects. Whereas pleural fluid from healthy controls contained mainly CD8+ T cells, benign or malignant pleural effusions included mainly CD4+ T cells. Effector memory T cells were the main T cell subpopulation in pleural fluid from healthy subjects. In contrast, there was a striking and selective recruitment of central memory CD4+ T cells in MPE, but not of effector cells CD8+ T cells or NK cells in the pleural fluid as one would expect in order to obtain an efficient immune response.

Conclusions

Comparing for the first time MPE to pleural fluid from healthy subjects, we found a local defect in recruiting effector CD8+ T cells, which may be involved in the escape of tumor cells from immune response. Further studies are needed to characterize which subtypes of effector CD8+ T cells are involved, opening prospects for cell therapy in MPE and MPM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sahn S: Malignant pleural effusions. Pleural disease. Edited by: Bouros D. 2004, London: Informa Healthcare, 411-438.CrossRef Sahn S: Malignant pleural effusions. Pleural disease. Edited by: Bouros D. 2004, London: Informa Healthcare, 411-438.CrossRef
2.
go back to reference Scherpereel A, et al: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010, 35 (3): 479-495. 10.1183/09031936.00063109.CrossRefPubMed Scherpereel A, et al: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010, 35 (3): 479-495. 10.1183/09031936.00063109.CrossRefPubMed
3.
go back to reference Robinson BW, Robinson C, Lake RA: Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer. 2001, 32 (2): 197-201. 10.1016/S0169-5002(00)00217-8.CrossRefPubMed Robinson BW, Robinson C, Lake RA: Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer. 2001, 32 (2): 197-201. 10.1016/S0169-5002(00)00217-8.CrossRefPubMed
4.
go back to reference Astoul P, et al: Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1998, 83 (10): 2099-2104. 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3.CrossRefPubMed Astoul P, et al: Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1998, 83 (10): 2099-2104. 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3.CrossRefPubMed
5.
go back to reference Boutin C, et al: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994, 74 (9): 2460-2467. 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N.CrossRefPubMed Boutin C, et al: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994, 74 (9): 2460-2467. 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N.CrossRefPubMed
6.
go back to reference Sebastian M, et al: Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother. 2009, 32 (2): 195-202. 10.1097/CJI.0b013e318195b5bb.CrossRefPubMed Sebastian M, et al: Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother. 2009, 32 (2): 195-202. 10.1097/CJI.0b013e318195b5bb.CrossRefPubMed
7.
go back to reference Hegmans JP, et al: Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med. 2005, 171 (10): 1168-1177. 10.1164/rccm.200501-057OC.CrossRefPubMed Hegmans JP, et al: Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med. 2005, 171 (10): 1168-1177. 10.1164/rccm.200501-057OC.CrossRefPubMed
8.
go back to reference Hegmans JP, et al: Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010, 181 (12): 1383-1390. 10.1164/rccm.200909-1465OC.CrossRefPubMed Hegmans JP, et al: Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010, 181 (12): 1383-1390. 10.1164/rccm.200909-1465OC.CrossRefPubMed
9.
go back to reference Sterman DH, et al: A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011, 184 (12): 1395-1399. 10.1164/rccm.201103-0554CR.CrossRefPubMedPubMedCentral Sterman DH, et al: A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011, 184 (12): 1395-1399. 10.1164/rccm.201103-0554CR.CrossRefPubMedPubMedCentral
10.
go back to reference Gregoire M: Dendritic cell vaccination as a treatment modality for mesothelioma. Expert Rev Respir Med. 2010, 4 (3): 311-314. 10.1586/ers.10.33.CrossRefPubMed Gregoire M: Dendritic cell vaccination as a treatment modality for mesothelioma. Expert Rev Respir Med. 2010, 4 (3): 311-314. 10.1586/ers.10.33.CrossRefPubMed
11.
go back to reference Antony VB, et al: Recruitment of inflammatory cells to the pleural space. Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol. 1993, 151 (12): 7216-7223.PubMed Antony VB, et al: Recruitment of inflammatory cells to the pleural space. Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol. 1993, 151 (12): 7216-7223.PubMed
12.
go back to reference Sallusto F, Lanzavecchia A: Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol. 2009, 39 (8): 2076-2082. 10.1002/eji.200939722.CrossRefPubMed Sallusto F, Lanzavecchia A: Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol. 2009, 39 (8): 2076-2082. 10.1002/eji.200939722.CrossRefPubMed
13.
go back to reference Sallusto F, et al: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999, 401 (6754): 708-712. 10.1038/44385.CrossRefPubMed Sallusto F, et al: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999, 401 (6754): 708-712. 10.1038/44385.CrossRefPubMed
14.
go back to reference Wherry EJ, et al: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003, 4 (3): 225-234.CrossRefPubMed Wherry EJ, et al: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003, 4 (3): 225-234.CrossRefPubMed
15.
go back to reference Harari A, et al: Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005, 174 (2): 1037-1045.CrossRefPubMed Harari A, et al: Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005, 174 (2): 1037-1045.CrossRefPubMed
16.
go back to reference Roberts AD, Woodland DL: Cutting edge: effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol. 2004, 172 (11): 6533-6537.CrossRefPubMed Roberts AD, Woodland DL: Cutting edge: effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol. 2004, 172 (11): 6533-6537.CrossRefPubMed
17.
go back to reference Klebanoff CA, Gattinoni L, Restifo NP: CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006, 211: 214-224. 10.1111/j.0105-2896.2006.00391.x.CrossRefPubMedPubMedCentral Klebanoff CA, Gattinoni L, Restifo NP: CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006, 211: 214-224. 10.1111/j.0105-2896.2006.00391.x.CrossRefPubMedPubMedCentral
18.
go back to reference Okamoto M, et al: T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest. 2005, 128 (6): 4030-4035. 10.1378/chest.128.6.4030.CrossRefPubMed Okamoto M, et al: T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest. 2005, 128 (6): 4030-4035. 10.1378/chest.128.6.4030.CrossRefPubMed
19.
go back to reference Aguiar LM, et al: Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization. Clinics (Sao Paulo). 2008, 63 (5): 637-644. 10.1590/S1807-59322008000500012.CrossRef Aguiar LM, et al: Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization. Clinics (Sao Paulo). 2008, 63 (5): 637-644. 10.1590/S1807-59322008000500012.CrossRef
20.
go back to reference Klimiuk J, et al: Lymphocyte and lymphocyte subsets in pleural fluid--comparison of malignant and non-malignant disorders. Pol Arch Med Wewn. 2004, 111 (3): 291-296.PubMed Klimiuk J, et al: Lymphocyte and lymphocyte subsets in pleural fluid--comparison of malignant and non-malignant disorders. Pol Arch Med Wewn. 2004, 111 (3): 291-296.PubMed
21.
go back to reference Scherpereel A, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006, 173 (10): 1155-1160. 10.1164/rccm.200511-1789OC.CrossRefPubMed Scherpereel A, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006, 173 (10): 1155-1160. 10.1164/rccm.200511-1789OC.CrossRefPubMed
22.
go back to reference Grigoriu BD, et al: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007, 13 (10): 2928-2935. 10.1158/1078-0432.CCR-06-2144.CrossRefPubMed Grigoriu BD, et al: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007, 13 (10): 2928-2935. 10.1158/1078-0432.CCR-06-2144.CrossRefPubMed
23.
go back to reference Noppen M, et al: Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med. 2000, 162: 1023-1026. 10.1164/ajrccm.162.3.9910050.CrossRefPubMed Noppen M, et al: Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med. 2000, 162: 1023-1026. 10.1164/ajrccm.162.3.9910050.CrossRefPubMed
24.
go back to reference Conover WJ, Iman RL: Analysis of covariance using the rank transformation. Biometrics. 1982, 38 (3): 715-724. 10.2307/2530051.CrossRefPubMed Conover WJ, Iman RL: Analysis of covariance using the rank transformation. Biometrics. 1982, 38 (3): 715-724. 10.2307/2530051.CrossRefPubMed
25.
go back to reference Baecher-Allan C, et al: CD4 + CD25high Regulatory cells in human peripheral blood. J Immunol. 2001, 167 (3): 1245-1253.CrossRefPubMed Baecher-Allan C, et al: CD4 + CD25high Regulatory cells in human peripheral blood. J Immunol. 2001, 167 (3): 1245-1253.CrossRefPubMed
26.
go back to reference Saule P, et al: Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev. 2006, 127: 274-281. 10.1016/j.mad.2005.11.001.CrossRefPubMed Saule P, et al: Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev. 2006, 127: 274-281. 10.1016/j.mad.2005.11.001.CrossRefPubMed
27.
go back to reference Atanackovic D, et al: Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res. 2004, 10 (8): 2600-2608. 10.1158/1078-0432.CCR-03-0239.CrossRefPubMed Atanackovic D, et al: Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res. 2004, 10 (8): 2600-2608. 10.1158/1078-0432.CCR-03-0239.CrossRefPubMed
28.
go back to reference Prado-Garcia H, et al: Effector, memory and naive CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer. 2005, 47 (3): 361-371. 10.1016/j.lungcan.2004.07.046.CrossRefPubMed Prado-Garcia H, et al: Effector, memory and naive CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer. 2005, 47 (3): 361-371. 10.1016/j.lungcan.2004.07.046.CrossRefPubMed
29.
go back to reference Khalil RY, Khalil MM: Flow cytometric study of T-cell subsets in lymphocytic pleural effusions. Cytometry. 1997, 30 (4): 204-205. 10.1002/(SICI)1097-0320(19970815)30:4<204::AID-CYTO8>3.0.CO;2-J.CrossRefPubMed Khalil RY, Khalil MM: Flow cytometric study of T-cell subsets in lymphocytic pleural effusions. Cytometry. 1997, 30 (4): 204-205. 10.1002/(SICI)1097-0320(19970815)30:4<204::AID-CYTO8>3.0.CO;2-J.CrossRefPubMed
30.
go back to reference Szyllo K, et al: The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis. Mediators Inflamm. 2003, 12 (3): 131-138. 10.1080/0962935031000134842.CrossRefPubMedPubMedCentral Szyllo K, et al: The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis. Mediators Inflamm. 2003, 12 (3): 131-138. 10.1080/0962935031000134842.CrossRefPubMedPubMedCentral
31.
go back to reference Lucivero G, Pierucci G, Bonomo L: Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J. 1988, 1 (4): 337-340.PubMed Lucivero G, Pierucci G, Bonomo L: Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J. 1988, 1 (4): 337-340.PubMed
32.
go back to reference San Jose ME, et al: Lymphocyte populations in tuberculous pleural effusions. Ann Clin Biochem. 1999, 36 (Pt 4): 492-500.CrossRefPubMed San Jose ME, et al: Lymphocyte populations in tuberculous pleural effusions. Ann Clin Biochem. 1999, 36 (Pt 4): 492-500.CrossRefPubMed
33.
go back to reference Jassar AS, et al: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005, 65 (24): 11752-11761. 10.1158/0008-5472.CAN-05-1658.CrossRefPubMed Jassar AS, et al: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005, 65 (24): 11752-11761. 10.1158/0008-5472.CAN-05-1658.CrossRefPubMed
34.
go back to reference Odaka M, et al: Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. 2001, 61 (16): 6201-6212.PubMed Odaka M, et al: Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. 2001, 61 (16): 6201-6212.PubMed
35.
go back to reference Zhang L, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003, 348 (3): 203-213. 10.1056/NEJMoa020177.CrossRefPubMed Zhang L, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003, 348 (3): 203-213. 10.1056/NEJMoa020177.CrossRefPubMed
36.
go back to reference Shankaran V, et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410 (6832): 1107-1111. 10.1038/35074122.CrossRefPubMed Shankaran V, et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410 (6832): 1107-1111. 10.1038/35074122.CrossRefPubMed
37.
go back to reference Balkwill F: Chemokine biology in cancer. Semin Immunol. 2003, 15 (1): 49-55. 10.1016/S1044-5323(02)00127-6.CrossRefPubMed Balkwill F: Chemokine biology in cancer. Semin Immunol. 2003, 15 (1): 49-55. 10.1016/S1044-5323(02)00127-6.CrossRefPubMed
38.
go back to reference Atanackovic D, et al: The local cytokine and chemokine milieu within malignant effusions. Tumour Biol. 2008, 29 (2): 93-104. 10.1159/000135689.CrossRefPubMed Atanackovic D, et al: The local cytokine and chemokine milieu within malignant effusions. Tumour Biol. 2008, 29 (2): 93-104. 10.1159/000135689.CrossRefPubMed
39.
go back to reference Hoffmann TK, et al: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002, 8 (8): 2553-2562.PubMed Hoffmann TK, et al: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002, 8 (8): 2553-2562.PubMed
40.
go back to reference Lockhart DC, et al: Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery. 2001, 129 (6): 749-756. 10.1067/msy.2001.114554.CrossRefPubMed Lockhart DC, et al: Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery. 2001, 129 (6): 749-756. 10.1067/msy.2001.114554.CrossRefPubMed
41.
go back to reference Oka M, et al: The characterization of peritoneal and pleural exudate cells from malignant effusions. Surg Today. 1993, 23 (6): 500-503. 10.1007/BF00730624.CrossRefPubMed Oka M, et al: The characterization of peritoneal and pleural exudate cells from malignant effusions. Surg Today. 1993, 23 (6): 500-503. 10.1007/BF00730624.CrossRefPubMed
42.
go back to reference Sikora J, Zeromski J: Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions. Folia Histochem Cytobiol. 2002, 40 (4): 347-351.PubMed Sikora J, Zeromski J: Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions. Folia Histochem Cytobiol. 2002, 40 (4): 347-351.PubMed
43.
go back to reference Whiteside TL: Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999, 48 (7): 346-352. 10.1007/s002620050585.CrossRefPubMed Whiteside TL: Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999, 48 (7): 346-352. 10.1007/s002620050585.CrossRefPubMed
44.
go back to reference Chen YQ, et al: CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion. Am J Respir Crit Care. 2005, 172 (11): 1434-1439. 10.1164/rccm.200504-588OC.CrossRef Chen YQ, et al: CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion. Am J Respir Crit Care. 2005, 172 (11): 1434-1439. 10.1164/rccm.200504-588OC.CrossRef
45.
go back to reference Delong P, et al: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005, 4 (3): 342-346. 10.4161/cbt.4.3.1644.CrossRefPubMed Delong P, et al: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005, 4 (3): 342-346. 10.4161/cbt.4.3.1644.CrossRefPubMed
46.
go back to reference Li H, et al: Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother. 2011, 60 (11): 1587-1596. 10.1007/s00262-011-1059-6.CrossRefPubMed Li H, et al: Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother. 2011, 60 (11): 1587-1596. 10.1007/s00262-011-1059-6.CrossRefPubMed
47.
go back to reference Qin XJ, et al: CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res. 2009, 15 (7): 2231-2237. 10.1158/1078-0432.CCR-08-2641.CrossRefPubMed Qin XJ, et al: CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res. 2009, 15 (7): 2231-2237. 10.1158/1078-0432.CCR-08-2641.CrossRefPubMed
48.
go back to reference Hegmans JP, et al: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006, 27 (6): 1086-1095. 10.1183/09031936.06.00135305.CrossRefPubMed Hegmans JP, et al: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006, 27 (6): 1086-1095. 10.1183/09031936.06.00135305.CrossRefPubMed
49.
go back to reference Stathopoulos GT, et al: A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008, 100 (20): 1464-1476. 10.1093/jnci/djn325.CrossRefPubMed Stathopoulos GT, et al: A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008, 100 (20): 1464-1476. 10.1093/jnci/djn325.CrossRefPubMed
50.
go back to reference Chen YM, et al: Elevation of interleukin-10 levels in malignant pleural effusion. Chest. 1996, 110 (2): 433-436. 10.1378/chest.110.2.433.CrossRefPubMed Chen YM, et al: Elevation of interleukin-10 levels in malignant pleural effusion. Chest. 1996, 110 (2): 433-436. 10.1378/chest.110.2.433.CrossRefPubMed
51.
go back to reference Colucci F, Di Santo JP, Leibson PJ: Natural killer cell activation in mice and men: different triggers for similar weapons?. Nat Immunol. 2002, 3 (9): 807-813. 10.1038/ni0902-807.CrossRefPubMed Colucci F, Di Santo JP, Leibson PJ: Natural killer cell activation in mice and men: different triggers for similar weapons?. Nat Immunol. 2002, 3 (9): 807-813. 10.1038/ni0902-807.CrossRefPubMed
52.
go back to reference Loza MJ, et al: Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood. 2002, 99 (4): 1273-1281. 10.1182/blood.V99.4.1273.CrossRefPubMed Loza MJ, et al: Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood. 2002, 99 (4): 1273-1281. 10.1182/blood.V99.4.1273.CrossRefPubMed
53.
go back to reference Yamada N, et al: CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010, 59 (10): 1543-1549. 10.1007/s00262-010-0881-6.CrossRefPubMed Yamada N, et al: CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010, 59 (10): 1543-1549. 10.1007/s00262-010-0881-6.CrossRefPubMed
54.
go back to reference Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP: Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer. 2012, 12: 580-10.1186/1471-2407-12-580.CrossRefPubMedPubMedCentral Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP: Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer. 2012, 12: 580-10.1186/1471-2407-12-580.CrossRefPubMedPubMedCentral
55.
go back to reference Thomas A, Hassan R: Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012, 13: e301-e310. 10.1016/S1470-2045(12)70126-2.CrossRefPubMed Thomas A, Hassan R: Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012, 13: e301-e310. 10.1016/S1470-2045(12)70126-2.CrossRefPubMed
Metadata
Title
Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid
Authors
Arnaud Scherpereel
Bogdan Dragos Grigoriu
Marc Noppen
Thomas Gey
Bachar Chahine
Simon Baldacci
Jacques Trauet
Marie-Christine Copin
Jean-Paul Dessaint
Henri Porte
Myriam Labalette
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-324

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine